HX575 Epoetin Alfa Subcutaneously (s.c.) in Chronic Kidney Disease (CKD)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 417 participants.
Also called NCT01576341
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 417 participants
- Sponsor
- Sandoz
- Registry
-
NCT01576341 -
2011-002871-40
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Germany, Italy, Poland, Romania, Russia, Türkiye, Ukraine
- Registry status
- Completed
Technical summary
Registry record NCT01576341. Allocation not applicable; no masking; primary purpose treatment. Start 2012-04 (registry gives no type); primary completion 2014-10 (actual). Results posted on 2017-06-19.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- HX575 Epoetin Alfa Subcutaneously (s.c.) in Chronic Kidney Disease (CKD)
- Acronym
- SENSE
- Condition
- Chronic Kidney Disease
- Intervention (Drug)
- HX575 epoetin alfa (Sandoz)
- Lead sponsor
- Sandoz
Record details
- Record id
cardio:ct-nct01576341- Content hash
69a753b901d779020fcfba5b1fb6771ff0e3c30f0f4465edee8871e6def4dbc1